The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Tandem transplantation in NDMM: auto-auto vs. auto-allo analysis
At the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, the pooled analysis of tandem autologous-autologous vs. autologous-allogeneic transplantation for 1,338 patients with newly diagnosed multiple myeloma from four trials with long-term follow-up was presented. Speaking from the meeting, Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, explains the results, taken from the BMT CTN 0102, NMAM2000, PETHEMA/GEM2000 and Torino consortium trials, and their impact.
